Humacyte, Inc. (HUMA)
NASDAQ: HUMA · Real-Time Price · USD
0.6585
-0.0229 (-3.36%)
Aug 21, 2026, 11:39 AM EDT - Market open
Humacyte Employees
Humacyte had 184 employees as of December 31, 2025. The number of employees decreased by 36 or -16.36% compared to the previous year.
Employees
184
Change (1Y)
-36
Growth (1Y)
-16.36%
Revenue / Employee
$11,527
Profits / Employee
-$525,370
Market Cap
182.93M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 184 | -36 | -16.36% | 184 | 0 |
| Dec 31, 2024 | 220 | 35 | 18.92% | 218 | 2 |
| Dec 31, 2023 | 185 | 21 | 12.80% | 183 | 2 |
| Dec 31, 2022 | 164 | 18 | 12.33% | 164 | 0 |
| Dec 31, 2021 | 146 | - | - | 145 | 1 |
Related Stocks
| Company Name | Employees |
|---|---|
| Innate Pharma | 164 |
| Coherus Oncology | 144 |
| Tonix Pharmaceuticals Holding | 142 |
| Voyager Therapeutics | 141 |
| Keros Therapeutics | 92 |
| Alpha Cognition | 71 |
| Korro Bio | 57 |
| PepGen | 57 |
HUMA News
- 2 days ago - Humacyte publishes V007 results in The Lancet Digital Health - TheFly
- 2 days ago - Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results - GlobeNewsWire
- 3 days ago - Board-Certified Vascular and Endovascular Surgeon Performs First Commercial Symvess® Implantation; Cites Bioengineered Blood Vessel as “Revolutionary Advancement” - GlobeNewsWire
- 4 days ago - Humacyte reports Q2 EPS (16c), consensus (10c) - TheFly
- 4 days ago - Humacyte price target lowered to $1 from $2 at Benchmark - TheFly
- 9 days ago - Humacyte Earnings Call Transcript: Q2 2026 - Transcripts
- 9 days ago - Humacyte Earnings release: Q2 2026 - Filings
- 9 days ago - Humacyte Quarterly report: Q2 2026 - Filings